The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Open-label single-group fMRI study administering a single 25 mg dose of COMP360 psilocybin to adults (18–55) with moderate MDD to assess changes in rumination and associated neural activity.

Primary outcomes include behavioural measures of rumination and neuroimaging markers; participants must taper psychotropic medications prior to baseline and have ongoing mental health care.